Thermo Fisher Scientific Inc. (NYSE:TMO) is among the 13 Best Nanotechnology Stocks to Buy Now. Morgan Stanley Analyst Is Bullish On Thermo Fisher Scientific Inc. (TMO) According to The Fly, on December 2, 2025, Morgan Stanley analyst Kallum Titchmarsh established a price objective of $670, up from $656. He initiated coverage of Thermo Fisher Scientific Inc. (NYSE:TMO) with an Overweight rating. According to Titchmarsh, the end markets for Life Science Tools and Diagnostics are starting to show potential ...

Financial giants have made a conspicuous bearish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:TMO) revealed 9 unusual trades.Delving into the details, we found 22% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $176,400, and 7 were calls, valued at $558,411.Projected Price TargetsBased on the trading activity, it appears that the significant investors are aiming for a price t ...

Core Insights - ClearBridge Investments reported that mid-cap stocks experienced growth in Q3 2025, driven by a favorable monetary policy environment and stabilizing earnings [1] - The Federal Reserve's rate cuts positively impacted small and mid-cap stocks, with value stocks outperforming growth stocks [1] - The ClearBridge Mid Cap Strategy outperformed the Russell Midcap Index, primarily due to stock selection in the consumer staples and healthcare sectors [1] Company-Specific Insights - Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $9.57 billion and focuses on life science reagents, instruments, and services [2] - The stock of Bio-Techne Corporation saw a one-month return of -0.32% and a 52-week decline of 15.36%, closing at $61.40 on November 12, 2025 [2] - ClearBridge initiated a new position in Bio-Techne, citing its high-margin consumables and instrumentation portfolio as key factors for its appeal as a growth-oriented investment [3] Financial Performance - In Q1 2026, Bio-Techne Corporation reported revenues of $286.6 million, reflecting a 1% year-over-year decline on both an organic and reported basis [4] - Despite the potential of Bio-Techne as an investment, the company is not among the most popular stocks among hedge funds, with 37 hedge fund portfolios holding its stock at the end of Q2 2025 [4]

Group 1 - Mairs & Power Balanced Fund reported a return of 2.66% in the first half of 2025, underperforming benchmark indexes which rose 5.43% and 5.67% respectively [1] - The fund's performance was impacted by external factors such as tariff uncertainty, conflicts in the Middle East, and rising national debt [1] - The fund experienced a recovery, rising 25% from its low at the beginning of the quarter [1] Group 2 - Bio-Techne Corporation (NASDAQ:TECH) has a market capitalization of $8.239 billion and focuses on life science reagents, instruments, and services [2] - The stock of Bio-Techne Corporation saw a one-month return of -5.87% and a 52-week decline of 29.39%, closing at $52.92 per share on September 23, 2025 [2] - The company underperformed due to uncertainty in the funding environment, influenced by federal funding cuts and a weak venture capital landscape [3] Group 3 - Bio-Techne Corporation generated $317 million in revenues in the fiscal fourth quarter of 2025, reflecting a 3% year-over-year increase on an organic basis and a 4% increase on a reported basis [4] - The company is not among the 30 most popular stocks among hedge funds, with 37 hedge fund portfolios holding its stock at the end of the second quarter, up from 34 in the previous quarter [4] - Despite acknowledging Bio-Techne's potential, the company believes certain AI stocks present greater upside potential and lower downside risk [4]